Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Discussions

For the past few years there have been discussions about discussions about discussions ad infinitum, with only Mr Lozano's failed attempt for inclusion on the ballot as evidence of anything concrete being attempted.

As long as Rule 14a-8 remains available to PTSC, absolutely nothing can be changed.

This would only leave a complete slate as a viable option to do something about changing the BoD, no matter how many further discussions are held.

Even if Rule 14a-11 was available next year, it would take a minimum of 3 more years to get a majority of shareholder nominees on the BoD, 4 if increased to 7 members. If the Rule is not applicable, one is looking at 6 or 7 more years, by which time most patents will have expired.

Additionally, PTSC could amend director qualification standards whereby prior experience as a director of a publicly traded company is a pre-requisite for inclusion on the proxy.

Discussion will not change the reality of the situation.

.

.

.

Be well

Share
New Message
Please login to post a reply